While the cause of the heterogeneous responses from different tumor cell lines to Hsp90 inhibitors remains little beyond speculations, such as post-translational modifications and multiple oncogenic factors in the cells, the above observations could have posted serious challenges for the patient selection processes of the previous clinical trials. This evidence concerns the gene HSP90AB1 and neoplasm.